NHS England has approved a new treatment for women with hard-to-treat ovarian cancer, marking the first new drug for resistant ovarian cancer to be authorized in over 20 years. The drug, mirvetuximab soravtansine, is intended for patients whose disease has become resistant to platinum-based chemotherapy and whose tumors express folate receptor-alpha, a protein targeted by the medication.

Ovarian cancer ranks as the 18th most common cancer worldwide, with over 300,000 women diagnosed annually. The disease is often detected at an advanced stage, making treatment more challenging. Standard care typically involves surgery followed by chemotherapy; however, approximately 80% of patients with advanced ovarian cancer experience relapse, and many develop resistance to chemotherapy over time.

The National Institute for Health and Care Excellence (NICE) issued final draft guidance recommending the use of mirvetuximab soravtansine for women with epithelial ovarian, fallopian tube, or peritoneal cancers that no longer respond to platinum chemotherapy. NHS England anticipates that up to 400 women in England could benefit from the new treatment each year.

Clinical evidence supporting the approval comes from a global trial involving eight NHS hospitals. The study demonstrated that patients receiving mirvetuximab soravtansine experienced delayed cancer progression and a survival benefit of approximately four months on average compared to those undergoing chemotherapy alone. The drug is administered intravenously once every three weeks.

Cancer specialists and patient advocates have welcomed the decision as a significant advancement. NHS England’s national clinical lead for cancer drugs, Professor Ruth Plummer, described the approval as the most substantial breakthrough in treatment for these difficult-to-treat ovarian cancers in more than two decades. Meanwhile, Victoria Clare, chief executive officer of the ovarian cancer charity Ovacome, called it a “landmark moment” for patients who previously had limited treatment options after developing chemotherapy resistance.

The introduction of mirvetuximab soravtansine offers renewed hope for women facing a form of ovarian cancer with historically poor outcomes and limited therapeutic alternatives. NHS England’s move signals a commitment to expanding access to innovative therapies that can improve survival and quality of life for patients with resistant ovarian cancer.